Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis

Autoři: Ming Yang aff001;  Xuejun Zhang aff001;  Jinlong Liu aff001
Působiště autorů: Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical University, Chengde, Hebei province, China aff001
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225170



Serum des-γ-carboxy prothrombin (DCP) is a hepatocellular carcinoma (HCC) tumor marker that can be used to assess patient prognosis. Since the value of DCP in predicting the prognosis of hepatocellular carcinoma patients treated with transarterial chemotherapy remains controversial, we performed a meta-analysis of previous clinical studies.


A systematic literature search was performed using PubMed, the MEDLINE database, EMBASE, and the Cochrane Library in accordance with the PRISMA guidelines. The hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the effect size.


Six respective cohort studies including a total of 943 cases were identified. The pooled results showed that low DCP was associated with a favorable overall survival (OS)(HR 0.653, 95% CI 0.444–0.960), and DCP response was associated with increased OS (HR 0.387,95% CI 0.215–0.697) and progression-free survival (PFS) (HR 0.42,95% CI 0.23–0.74) in HCC patients treated with transarterial chemotherapy.


DCP values in HCC patients undergoing hepatic arterial chemotherapy seem to be associated with OS and PFS. Thus, monitoring DCP values and observing the DCP response should be part of the management of patients undergoing transarterial chemotherapy.

Klíčová slova:

Cancer chemotherapy – Cancer treatment – Hepatocellular carcinoma – Chemotherapy – Prognosis – Serine proteases – Systematic reviews


1. Toyoda Hidenori, Kumada Takashi, Osaki Yukio,Toshifumi Tada1,Yuji Kaneoka,Atsuyuki Maeda. A Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer science,2012,103(5):921–925. doi: 10.1111/j.1349-7006.2012.02232.x 22320249

2. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SDet al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. The New England Journal of Medicine,1984,310: 1427–1431. doi: 10.1056/NEJM198405313102204 6201741

3. Kim HR, Bisceglie A, Wright SE, Dienstag JL, Lee SM, Sterling RK, Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010, 138(2):493–502. doi: 10.1053/j.gastro.2009.10.031 19852963

4. Yu Rentao, Tan Zhaoxia, Xiang Xiaomei, Dan Yunjie, Deng Guohong, Rentao Yu et al. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer, 2017, 17(1):608. doi: 10.1186/s12885-017-3609-6 28863782

5. Nishikawa H, Osaki Y, Kita R, Kimura T, Ohara Y, Takeda H et al. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma. Oncology reports, 2014,31: 65–72. doi: 10.3892/or.2013.2845 24220763

6. Yamasaki T and Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatology Research,2012, 42(4):340–348. doi: 10.1111/j.1872-034X.2011.00938.x 22151009

7. Issei Saeki, Takahiro Yamasaki, Norikazu Tanabe, Takuya Iwamoto, Toshihiko Matsumoto, Yohei Urata et al. A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy. PLOS ONE, 2015, 10(5).

8. Lee Yong Kang, Kim Seung Up, Kim Do Young, Ahn Sang Hoon, Lee Kwang Hun, Lee Do Yunet al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer, 2013, 13(1).

9. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement.The Journal of the American Medical Association,2015, 313.

10. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 2010, 25(9):603–605. doi: 10.1007/s10654-010-9491-z 20652370

11. Tierney Jayne F, Stewart Lesley A, Ghersi Davina, Burdett Sarah, Sydes Matthew R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8(1):16. doi: 10.1186/1745-6215-8-8

12. Park Won-Hyeong, Shim Ju-Hyun, Han Seung-Bong, Won Hyung-Jin, Shin Yong-Moon, Kim Kang-Moet al. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Vascular & Interventional Radiology, 2012, 23(7):927–936.

13. Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T et al. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatology international,2017; 11: 105–114. doi: 10.1007/s12072-016-9771-0 27766479

14. Ha Lee Myoung, Up Kim Seung, Young Kim Do, Hoon Ahn Sang, Hee Choi Eun, Hun ee Kwanget al. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. Journal of gastroenterology and hepatology,2012; 27: 313–322. doi: 10.1111/j.1440-1746.2011.06867.x 21793906

15. Suehiro Taketoshi, Matsumata Takashi, Itasaka Hidetoshi, Taketomi Akinobu, Yamamoto Kazuharu, Sugimachi Keizo et al. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery,1995; 117: 682–691. doi: 10.1016/s0039-6060(95)80013-1 7539944

16. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor Markers in Early Diagnosis, Follow-Up and Management of Patients with Hepatocellular Carcinoma. Oncology, 2002, 62(1):57–63.

17. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α ‐fetoprotein alone and those seropositive for des‐ γ ‐carboxy prothrombin alone. Journal of Gastroenterology & Hepatology,2010; 16: 1290–1296.

18. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma[J]. Journal of Gastroenterology, 2006, 41(12):1214–1219. doi: 10.1007/s00535-006-1950-7 17287901

19. Miyaaki Hisamitsu, Nakashima Osamu, Kurogi Mina, Eguchi Katsumi, Kojiro Masamichi. Lens culinarisagglutinin-reactive α-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. Journal of Gastroenterology, 2007, 42(12):962–968. doi: 10.1007/s00535-007-2117-x 18085353

20. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KHet al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.Journal of Clinical Gastroenterology, 2009, 43(5):482–488. doi: 10.1097/MCG.0b013e318182015a 19197197

21. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma. Oncology, 2010, 78(1):148–153.

22. Levasicc N, Lesnik LA, Garbajs M, Dezman R et. Prognostic Factors for Survival in Patients with Hepatocellular Carcinoma Treated By Transarterial Chemoembolization Using Drug-Eluting Beads. Journal of Clinical & Experimental Oncology,2018,7(5).

23. Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CWet al.Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. Journal of Clinical Gastroenterology, 2014, 48(8):734. doi: 10.1097/MCG.0b013e3182a8a254 24100755

24. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist, 2009, 14(7):717–725. doi: 10.1634/theoncologist.2009-0038 19581525

25. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone Get al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transplantation,2013,19: 1108–1118. doi: 10.1002/lt.23706 23873764

26. Herber S, Biesterfeld S, Franz U, Schneider J, Thies J, Schuchmann M et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovascular & Interventional Radiology, 2008, 31(4):768–777.

27. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer, 2003, 97(4):1042–1050. doi: 10.1002/cncr.11111 12569604

28. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL et al.EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, doi: 10.1016/j.jhep.2018.03.019 29628281

29. Daisuke Miyaki, Hiroshi Aikata, Hiromi Kan, Hatsue Fujino, Ayako Urabe, Keiichi Masaki et al. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. Journal of Gastroenterology and Hepatology, 2013, 28(12):1834–1841. doi: 10.1111/jgh.12311 23808713

Článek vyšel v časopise


2019 Číslo 11